Photocure

Executive Summary

Photocure is a Norwegian diagnostics company specializing in photodynamic technologies for cancer detection. Its flagship product, Cysview (hexaminolevulinate), is approved for use in blue light cystoscopy to improve the detection of non-muscle invasive bladder cancer. The company’s mission is to deliver transformative solutions that improve patient outcomes, particularly in urological oncology. With over two decades of experience, Photocure has established a strong foothold in the bladder cancer diagnostics market, where its technology helps reduce recurrence rates by enabling more complete tumor resections. Photocure continues to expand its pipeline through clinical studies evaluating Cysview in other cancer indications, such as upper tract urothelial carcinoma and potentially lung or gastrointestinal cancers. The company also seeks strategic partnerships to broaden global access to its technology. Given its approved product and ongoing R&D, Photocure is well-positioned for growth, though reliance on a single product and regulatory hurdles pose risks. The near-term outlook is supported by potential label expansions and commercialization efforts.

Upcoming Catalysts (preview)

• H1 2027FDA approval for Cysview in upper tract urothelial carcinoma60% success
• Q4 2026Strategic partnership for Asian market expansion70% success
• H2 2027Positive Phase 3 results for Cysview in a non-bladder indication50% success